Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02124395 · ClinicalTrials.gov registry record
Health-related Quality of Life in Rare Kidney Stone
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 365
- Enrollment target
NCT02124395: Completed study, sponsored by NYU Langone Health.
NCT02124395 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 365 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02124395 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 365 participants
- Enrollment target
Study Summary
Assessment of Health-related Quality of Life in Rare Kidney Stone Formers in the Rare Kidney Stone Consortium
Primary Outcome
Assessment of HRQoL in patients with rare kidney stones. Comparison of HRQoL results between rare kidney stone formers, general population and other populations with relevant chronic diseases
Interventions
- OTHER Health-related Quality of Life in Rare Kidney Stone Questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2013-08 |
| Est. Completion | 2022-07 |
What the finished NCT02124395 record still lists
NCT02124395 is an observational study that tracks outcomes without assigning an intervention. The registered 365 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Health-related Quality of Life in Rare Kidney Stone Questionnaire is the first listed.
NCT02124395 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02124395 about?
NCT02124395 is a clinical study titled "Health-related Quality of Life in Rare Kidney Stone". Assessment of Health-related Quality of Life in Rare Kidney Stone Formers in the Rare Kidney Stone Consortium
What is the current status of trial NCT02124395?
This trial is currently completed. The enrollment target is 365 participants. The study started on 2013-08. Estimated completion is 2022-07.
What interventions are being tested in trial NCT02124395?
The interventions under investigation include: Health-related Quality of Life in Rare Kidney Stone Questionnaire (OTHER).
Who is sponsoring clinical trial NCT02124395?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
- NCT05065840 · 365 participants · NA
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
- NCT05303519 · 365 participants · Phase 3
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- NCT05592626 · 365 participants · Phase 1
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia